PRMT7 and chronic myelogenous leukemia, BCR-ABL1 positive: Another promising compound, JS1310, targets PRMT7 by reprogramming glycine metabolism to elevate intracellular methylglyoxal levels, thereby impairing the self-renewal capacity of CML stem cells [445].